Organogenesis ‘commends’ final local coverage determinations

Organogenesis (ORGO) commends the decision by the U.S. Centers for Medicare & Medicaid Services on local coverage determination based on peer-reviewed and evidence-based data of clinical efficacy. The LCD covers skin substitute grafts/cellular and tissue-based products for the treatment of diabetic foot ulcers and venous leg ulcers in the Medicare population and is now set to become effective on February 12, 2025. Organogenesis offers 4 products for DFUs, including NuShield, and 2 for VLUs.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See Insiders’ Hot Stocks on TipRanks >>

Read More on ORGO:

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Tags

More Related Articles

Info icon

This data feed is not available at this time.

Data is currently not available

Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.